Severe hemolytic transfusion reaction due to anti-A1 following allogeneic stem cell transplantation with minor ABO incompatibility

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
Ciğdem Akalın AkkökLorentz Brinch

Abstract

Blood components should be compatible both with the recipient and the donor in the ABO incompatible allogeneic stem cell transplantation setting. A patient with blood type A2 received peripheral blood stem cells from a blood type O donor. The patient was in critical condition due to treatment-related toxicity. He had acquired anti-A1 that was unfortunately overlooked. Following transfusion of A1 red blood cells in error, he developed a severe hemolytic transfusion reaction. Anti-A1 is rarely clinically significant. We discuss the role of passenger lymphocytes in development of the anti-A1, and stress the importance of investigating unusual/atypical reactions in blood typing.

References

Mar 19, 2008·Bone Marrow Transplantation·H J LeeS O Ciurea

❮ Previous
Next ❯

Citations

May 28, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M JeyakanthanL J West
Feb 28, 2018·Transfusion·Floris HelmichFedde van der Graaf
Oct 30, 2020·International Journal of General Medicine·Muhammad SaboorSaleh Abdullah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.